NEDA is here, it here to stay and it is evolving. #MSBlog #MSResearch
“As promised; my platform presentation from yesterday. It is clear that treat-2-target is getting a lot of attention at this meeting as well as end-organ damage. There was a prestentation yesterday by Professor Ludwig Kappos to try and incorporate brain atrophy into the measurement; i.e. NEDA-4. This indicates that NEDA is behaving the way it should an evolving over time.”
“As promised; my platform presentation from yesterday. It is clear that treat-2-target is getting a lot of attention at this meeting as well as end-organ damage. There was a prestentation yesterday by Professor Ludwig Kappos to try and incorporate brain atrophy into the measurement; i.e. NEDA-4. This indicates that NEDA is behaving the way it should an evolving over time.”
CoI: multiple
This is great information – thank you.How different does this look if you monitor NEDA at the person level across the years (i.e. percent continuously NEDA)? Is Tecfidera really completely stopping disease activity in 50% of people or is it just making activity infrequent enough in 100% of people that you only catch it ever 2 years or so?Also, isn't ~25% NEDA for a placebo group surprisingly high? My impression was the "benign" MS course was somewhat of a fantasy, but this suggests otherwise.